Inside Innovation

Alpine Immune Sciences announced it is raising approximately $91 million to continue developing two drugs through a private placement. Frazier Life Sciences Public Fund is

A-Alpha Bio, a Seattle-based startup raised $20 million in a Series A funding round to continue studying which proteins bind with each other. Moving forward

Impel NeuroPharma announced Trudhesa, a drug used to treat migraines, has officially received approval from the U.S. Food and Drug Administration. John Hoekman originally co-founded

During an era of mass investment in the biotech industry and vast innovation, many technology company executives are making the switch to the life science

Out of the 11 biotech companies entering the public market in the last year, eight have been from Washington state. Just this summer, three companies,

Washington-based biotech company, Bristol Myers Squibb, has received a December 23rd decision date from the FDA. If passed, Orencia, a drug originally approved for patients

Real estate investment into the life sciences reached more than $9 billion in the first half of 2021, signaling a potential record-breaking year for industry

Washington is the third cleanest state in the U.S. according to a recent study by Filter King, an air filter delivery company The results of

Last week, Sonoma Biotherapeutics announced it raised $265 million to expand both its Seattle and San Francisco operations. One of the many perks of having

After announcing its new location in Redmond, Washington last week, Evotec says their first order of business in the new 130,000-square-foot campus is to develop

In a partnership with Google, Seattle-based company Lumen BioScience can now use machine learning as a tool to expedite and streamline production of its plant-based

Last week, Seagen, a Washington-based biotech company, announced a deal with China-based RemeGen Co., Ltd. The deal, valued at $2.6 billion, allows Seagen to develop